Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Net Margin (2016 - 2026)

Ironwood Pharmaceuticals' Net Margin history spans 16 years, with the latest figure at 271.81% for Q4 2025.

  • On a quarterly basis, Net Margin rose 45384.0% to 271.81% in Q4 2025 year-over-year; TTM through Dec 2025 was 52.69%, a 9999.0% increase, with the full-year FY2025 number at 52.66%, up 9995.0% from a year prior.
  • Net Margin hit 271.81% in Q4 2025 for Ironwood Pharmaceuticals, up from 32.87% in the prior quarter.
  • Over the last five years, Net Margin for IRWD hit a ceiling of 376.14% in Q2 2021 and a floor of 1014.62% in Q2 2023.
  • Historically, Net Margin has averaged 14.62% across 5 years, with a median of 34.08% in 2021.
  • Biggest five-year swings in Net Margin: tumbled -105276bps in 2023 and later surged 101371bps in 2024.
  • Tracing IRWD's Net Margin over 5 years: stood at 35.3% in 2021, then surged by 203bps to 106.95% in 2022, then tumbled by -224bps to 132.47% in 2023, then crashed by -37bps to 182.03% in 2024, then skyrocketed by 249bps to 271.81% in 2025.
  • Business Quant data shows Net Margin for IRWD at 271.81% in Q4 2025, 32.87% in Q3 2025, and 27.71% in Q2 2025.